UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Journal of Crohn's and colitis, 2020-02, Vol.14 (2), p.192-204

2020

Link zum Volltext

Verfügbarkeit prüfen

Post-marketing Safety Experience with Vedolizumab: Malignancy: 693

The American journal of gastroenterology, 2016-10, Vol.111, p.S313-S314

2016

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (1), p.149-157

2020

Link zum Volltext

Verfügbarkeit prüfen

Su1876 - Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S580

2017

Link zum Volltext

Verfügbarkeit prüfen

P014 The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data

The American journal of gastroenterology, 2019-07, Vol.114 (1), p.S4-S4

2019

Link zum Volltext

Verfügbarkeit prüfen

Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-876-S-876

2019

Link zum Volltext

Verfügbarkeit prüfen

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Inflammatory bowel diseases, 2018-10, Vol.24 (11), p.2431-2441

2018

Link zum Volltext

Verfügbarkeit prüfen

Post-marketing Safety Experience with Vedolizumab: Skin Reactions (Psoriasiform and Eczematous): 691

The American journal of gastroenterology, 2016-10, Vol.111, p.S313

2016

Link zum Volltext

Verfügbarkeit prüfen

Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis

Expert review of gastroenterology & hepatology, 2021-06, Vol.15 (6), p.711-722

2021

Link zum Volltext

Verfügbarkeit prüfen

P038 Comparing the Efficacy and Safety of Subcutaneous Vedolizumab Versus Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-Analysis

The American journal of gastroenterology, 2019-12, Vol.114 (1), p.S10-S10

2019

Link zum Volltext

Verfügbarkeit prüfen

P039 Integrating Maintenance Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: A Network Meta-Analysis

The American journal of gastroenterology, 2019-12, Vol.114 (1), p.S10-S10

2019

Link zum Volltext

Verfügbarkeit prüfen

Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S580

2017

Link zum Volltext

Verfügbarkeit prüfen

P011 A number needed to harm analysis of safety outcomes from randomized controlled trials of biologics and tofacitinib in ulcerative colitis

The American journal of gastroenterology, 2019-07, Vol.114 (1), p.S3-S4

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-628-S-628

2019

Link zum Volltext

Verfügbarkeit prüfen

Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-362-S-362

2018

Link zum Volltext

Verfügbarkeit prüfen

Sa1699 - Safety of Vedolizumab in Patients Naïve to Treatment with TNF Antagonists Compared with Patients with Prior use of TNF Antagonists

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-360-S-361

2018

Link zum Volltext

Verfügbarkeit prüfen

Post-Marketing Safety Experience of Vedolizumab in Patients With Pre-existing Viral Hepatitis: 712

The American journal of gastroenterology, 2017-10, Vol.112, p.S393

2017

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

Gastroenterology report, 2019-10, Vol.7 (5), p.322-330

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1865 - Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S575-S576

2017

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S575-S576

2017

Link zum Volltext

Verfügbarkeit prüfen

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

Journal of Crohn's and colitis, 2018-07, Vol.12 (8), p.905-919

2018

Link zum Volltext

Verfügbarkeit prüfen

Su1877 - Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S581

2017

Link zum Volltext

Verfügbarkeit prüfen

P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Gastroenterology (New York, N.Y. 1943), 2018-01, Vol.154 (1), p.S82-S82

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S581

2017

Link zum Volltext

Verfügbarkeit prüfen

P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Inflammatory bowel diseases, 2018-01, Vol.24 (suppl_1), p.S57-S58

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(67)
Bücher
(1)

Sprache

Englisch
(68)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Post-marketing Safety Experience with Vedolizumab: Malignancy: 693

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

Su1876 - Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

P014 The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data

Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Post-marketing Safety Experience with Vedolizumab: Skin Reactions (Psoriasiform and Eczematous): 691

Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis

P038 Comparing the Efficacy and Safety of Subcutaneous Vedolizumab Versus Adalimumab for the Treatment of Ulcerative Colitis: A Network Meta-Analysis

P039 Integrating Maintenance Efficacy and Safety of Vedolizumab and Other Advanced Therapies for the Treatment of Ulcerative Colitis: A Network Meta-Analysis

Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

P011 A number needed to harm analysis of safety outcomes from randomized controlled trials of biologics and tofacitinib in ulcerative colitis

Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data

Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease

Sa1699 - Safety of Vedolizumab in Patients Naïve to Treatment with TNF Antagonists Compared with Patients with Prior use of TNF Antagonists

Post-Marketing Safety Experience of Vedolizumab in Patients With Pre-existing Viral Hepatitis: 712

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

Su1865 - Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

Su1877 - Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

P155 REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS

Suchergebnisse filtern